MET Copy Number Gain Associates with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer

被引：1
|
作者：
Yano, Seiji [1 ]
Nanjo, Shigeki [1 ]
Arai, Sachiko [1 ]
Takeuchi, Shinji [1 ]
Yamada, Tadaaki [1 ]
Okada, Yasunori [2 ]
Hata, Akito [3 ]
Katakami, Nobuyuki [3 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa, Japan
[2] Juntendo Univ, Tokyo, Japan
[3] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
CNS Metastasis; osimertinib; MET copy number gain; EGFR-TKI resistance;
D O I：
10.1016/j.jtho.2016.11.269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA08.03
引用
收藏
页码：S272 / S273
页数：2
相关论文
共 50 条
  • [21] Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma
    Jiao, Demin
    Chen, Yu
    Liu, Xiang
    Tang, Xiali
    Chen, Jun
    Liu, Yongyang
    Jiang, Chunyan
    Chen, Qingyong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 682 : 371 - 380
  • [22] Clinical implications of MET gene copy number in lung cancer
    Toschi, Luca
    Cappuzzo, Federico
    FUTURE ONCOLOGY, 2010, 6 (02) : 239 - 247
  • [23] A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib
    Chu, Xiao
    Li, Yuan
    Zhu, Zhengfei
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : E211 - E214
  • [24] High copy number of the MET gene predicts resistance to EGFR-TKI in non-small cell lung cancer patients.
    Noro, Rintaro
    Seike, Masahiro
    Soeno, Chie
    Matsuda, Kuniko
    Sugano, Teppei
    Nishijima, Nobuhiko
    Toyokawa, Masaru
    Kitamura, Kazuhiro
    Kosaihira, Seiji
    Minegishi, Yuji
    Yoshimura, Akinobu
    Kubota, Kaoru
    Gemma, Akihiko
    CANCER RESEARCH, 2012, 72
  • [25] COMBINED THERAPY WITH NEXT GENERATION EGFR INHIBITOR AND MET KINASE INHIBITOR FOR OVERCOMING THE RESISTANCE IN EGFR MUTANT LUNG CANCER
    Nanjo, Shigeki
    Yamada, Tadaaki
    Nakagawa, Takayuki
    Takeuchi, Shinji
    Mitsudomi, Tetsuya
    Yano, Seiji
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S453 - S453
  • [26] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib
    Gu, Zhen-Bang
    Liao, Ling-Min
    Yao, Gong-Ji
    Fang, Ming
    Huang, Long
    CURRENT PROBLEMS IN CANCER, 2021, 45 (05)
  • [28] Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer
    Choi, Mihong
    Keam, Bhumsuk
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    CLINICAL LUNG CANCER, 2019, 20 (04) : E442 - E451
  • [29] Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
    Nakagawa, Takayuki
    Takeuchi, Shinji
    Yamada, Tadaaki
    Nanjo, Shigeki
    Ishikawa, Daisuke
    Sano, Takako
    Kita, Kenji
    Nakamura, Takahiro
    Matsumoto, Kunio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    Sekido, Yoshitaka
    Uenaka, Toshimitsu
    Yano, Seiji
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2149 - 2157
  • [30] Attacking EGFR mutant lung cancer by combined EGFR and c-Met inhibition
    Ortiz-Cuaran, Sandra
    Schoettle, Jakob
    Dahmen, Ilona
    Peifer, Martin
    Wieczoreck, Caroline
    Koker, Mirjam
    Ihle, Michaela A.
    Florin, Alexandra
    Pinther, Berit
    Heukamp, Lukas C.
    Ullrich, Roland T.
    Thomas, Roman K.
    CANCER RESEARCH, 2014, 74 (19)
12345